Sponsor Directory

AbbVie clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

816

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Healthy Volunteer
Interventions: ABBV-903 Tablet Form 1, ABBV-903 Tablet Form 2; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Rheumatoid Arthritis
Interventions: Placebo to Upadacitinib, Methotrexate, Placebo to Methotrexate, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 1,002 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 32
States / cities: La Mesa, California • Palm Desert, California • Daytona Beach, Florida + 26 more

Conditions: Cystic Fibrosis
Interventions: ABBV-3067, Placebo ABBV-3067, ABBV-2222, Placebo ABBV-2222; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 10
States / cities: Little Rock, Arkansas • Tampa, Florida • Iowa City, Iowa + 6 more

Conditions: Healthy
Interventions: ABBV-CLS-7262; Drug
Lead sponsor: Calico Life Sciences LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Chronic Lymphocytic Leukemia
Interventions: ABT-263; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 6
States / cities: La Jolla, California • Boston, Massachusetts • Omaha, Nebraska + 3 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost SR, LUMIGAN; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Dothan, Alabama • Newport Beach, California • Roswell, Georgia + 3 more

Conditions: Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
Interventions: ABT-199, Rituximab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 4
States / cities: La Jolla, California • Chicago, Illinois • New Hyde Park, New York + 1 more

Conditions: Exocrine Pancreatic Insufficiency (EPI)
Interventions: Pancrelipase, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 21 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 27 more

Conditions: Migraine
Interventions: Ubrogepant 100 mg, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more

Conditions: Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Neuroblastoma
Interventions: chemotherapy, venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 0 Years to 25 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 8 more

Conditions: Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
Interventions: Posaconazole, ABT-199, Decitabine, Azacitidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 60 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 13
States / cities: Duarte, California • Sacramento, California • Aurora, Colorado + 8 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: Temozolomide, Depatuxizumab mafodotin, Radiation, Placebo for ABT-414; Drug · Radiation
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 691 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 68
States / cities: Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 52 more

About this AbbVie sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AbbVie is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AbbVie trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AbbVie clinical trials

Filter and sort this sponsor

Live official records

A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants

A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects

A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

About this AbbVie sponsor directory page